Table 3. Postoperative and long term outcomes after treatment of first recurrent HCC.
| Repeat SR (n = 43) | RFA (n = 57) | P | |
|---|---|---|---|
| Operation related complications | 7 (16%) | 4 (7%) | 0.14 |
| Pleural effusion | 1 | 2 | 0.73 |
| Pneumothorax | 0 | 1 | 0.38 |
| Wound infection | 1 | 0 | 0.25 |
| Intraabdominal hemorrhage | 0 | 0 | 1.00 |
| Sepsis | 5 | 2 | 0.12 |
| Bile duct injury/Bile leakage | 3 | 1 | 0.19 |
| Hospital mortality | 1 (2%) | 0 (0%) | 0.25 |
| Total hospital day (day) | 13 (5–27) | 5 (2–17) | < 0.05 |
| Overall treatment response | 100% | 98% | 0.67 |
| Complete response | 42 | 55 | |
| Partial response | 1 | 1 | |
| Stable disease | 0 | 1 | |
| Progressive disease | 0 | 0 | |
| Median time from 1st recurrence to 2nd recurrence (m) | 11 (4–82) | 10 (0–87) | 0.74 |
| 2nd recurrence pattern | |||
| No recurrence | 13 (30%) | 16 (28%) | |
| Intrahepatic recurrence | 29 (67%) | 39 (68%) | |
| Extrahepatic recurrence | 1 (3%) | 2 (4%) | |
| Management of second intrahepatic recurrence | |||
| OP | 8 (27%) | 3 (8%) | |
| PEI | 2 (7%) | 7 (18%) | |
| RFA | 6 (21%) | 16 (41%) | |
| TACE | 13 (45%) | 13 (33%) | |
| Others (HAIC, Sorafenib, R/T, palliation) | 0 (0%) | 0 (0%) |